Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „daily“
Suchtreffer
Begriffe & Kennungen
Bosulif · 4.5 · Following concomitant administration of a single dose bosutinib with 6 daily doses of 600 mg rifampicin, in 24
Eintrag öffnenBosulif · 4.5 · In a study of 24 healthy subjects in whom 5 daily doses of 400 mg ketoconazole (a strong CYP3A inhibitor) were
Eintrag öffnenBraftovi · 4.8 · The encorafenib single agent (300 mg orally once daily) safety profile is based on data from 217 patients with
Eintrag öffnenBraftovi · 4.8 · The safety of encorafenib (300 mg orally once daily) in combination with binimetinib (45 mg orally twice daily
Eintrag öffnenBraftovi · 4.8 · The safety of encorafenib (300 mg orally once daily) in combination with cetuximab (dosed as per its SmPC) was
Eintrag öffnenBraftovi · 4.8 · The safety of encorafenib (300 mg orally once daily) in combination with cetuximab and FOLFOX was evaluated in
Eintrag öffnenBraftovi · 4.8 · The safety of encorafenib (450 mg orally once daily) in combination with binimetinib (45 mg orally twice daily
Eintrag öffnenBraftovi · 4.8 · When encorafenib was used at a dose of 300 mg once daily in combination with binimetinib 45 mg twice daily (Co
Eintrag öffnenBrilique · 4.8 · In PEGASUS, TIMI Major bleeding for ticagrelor 60 mg twice daily was higher than for ASA alone. No increased b
Eintrag öffnenBrilique · 4.8 · In PEGASUS, TIMI Major bleeding for ticagrelor 60 mg twice daily was higher than for ASA alone. No increased b
Eintrag öffnenBrilique · 4.8 · In PEGASUS, TIMI Major bleeding for ticagrelor 60 mg twice daily was higher than for ASA alone. No increased b
Eintrag öffnenBrilique · 4.8 · In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of pati
Eintrag öffnenBrilique · 4.8 · In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of pati
Eintrag öffnenBrilique · 4.8 · In PEGASUS, dyspnoea was reported in 14.2% of patients taking ticagrelor 60 mg twice daily and in 5.5% of pati
Eintrag öffnenBrilique · 4.8 · Ticagrelor 60 mg twice ASA alone daily + ASA N=6996 N=6958 Hazard Ratio Safety Endpoints KM% KM% p-value (95%
Eintrag öffnenBrilique · 4.8 · Ticagrelor 60 mg twice ASA alone daily + ASA N=6996 N=6958 Hazard Ratio Safety Endpoints KM% KM% p-value (95%
Eintrag öffnenBrilique · 4.8 · Ticagrelor 60 mg twice ASA alone daily + ASA N=6996 N=6958 Hazard Ratio Safety Endpoints KM% KM% p-value (95%
Eintrag öffnenBrilique · 4.8 · Ticagrelor 90 mg Clopidogrel twice daily N=9186 p-value* N=9235 PLATO Total Major 11.6 11.2 0.4336 PLATO Major
Eintrag öffnenBrilique · 4.8 · Ticagrelor 90 mg Clopidogrel twice daily N=9186 p-value* N=9235 PLATO Total Major 11.6 11.2 0.4336 PLATO Major
Eintrag öffnenBrilique · 4.8 · Ticagrelor 90 mg Clopidogrel twice daily p-value* N=9235 N=9186 PLATO Total Major 11.6 11.2 0.4336 PLATO Major
Eintrag öffnen